Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

NCT06931704 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

176

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Elranatamab
DRUG: Daratumumab
DRUG: Lenalidomide

Sponsor

Nantes University Hospital